Onconetix, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Onconetix, Inc. (ONCO) on September 11, 2026. The filing discloses the entry into a material definitive agreement and related Regulation FD disclosure regarding a loan facility extended to Realbotix, LLC.
Key Financial Metrics and Transaction Details
- Loan Facility: Onconetix entered into a Grid Promissory Note with Realbotix, LLC for an aggregate principal amount of up to $5.0 million.
- Initial Advance: $2.5 million was advanced on September 11, 2026.
- Interest Terms: The Note is non-interest bearing until the earlier of the closing of the pending Share Exchange Agreement or its termination. If terminated, interest accrues at 12% per annum.
- Maturity Date: September 11, 2027.
- Security: The Note is an unsecured obligation of Realbotix, guaranteed by Realbotix Corp.
- Use of Proceeds: General corporate and working capital purposes for Realbotix.
Material Changes and Related Agreements
This transaction is directly linked to the Share Exchange Agreement dated February 11, 2026, under which Onconetix agreed to acquire all equity interests of Realbotix in exchange for newly issued common stock. Key conditions include:
- Closing Condition: Onconetix must have at least $12.5 million in Net Cash at closing.
- Automatic Cancellation: Upon closing of the Realbotix Transaction, the Note and all obligations will be automatically cancelled and discharged.
- Net Cash Adjustment: The Net Cash at Closing calculation under the Share Exchange Agreement will be increased by $500,000 plus the aggregate principal amount outstanding under the Note.
Guidance, Risks, and Contingencies
The filing does not provide specific financial guidance, revenue projections, or liquidity metrics for Onconetix itself. The primary contingency is the successful consummation of the Realbotix Transaction. If the Share Exchange Agreement is terminated, the Note becomes a standard debt instrument with 12% annual interest, creating a potential receivable for Onconetix rather than an equity acquisition.
Investor Verification Checklist
- Verify Onconetix's current Net Cash position to assess the ability to meet the $12.5 million closing condition for the Realbotix acquisition.
- Review the full text of the Share Exchange Agreement (dated February 11, 2026) for other closing conditions not detailed in this 8-K.
- Monitor the status of the Realbotix Transaction to determine if the Note will be cancelled or converted to an interest-bearing receivable.
- Assess the creditworthiness of Realbotix Corp. as the guarantor of the $5.0 million facility.